hypertension

Photo
26.07.2023 • News

Roche Teams up with Alnylam for Antihypertensive Drug

Swiss pharmaceutical company Roche will collaborate with Cambridge, Massachusetts-based US biotech Alnylam Pharmaceuticals to further develop its drug zilebesiran for the treatment of hypertension. The therapeutic, which is in Phase 2 clinical trials, uses the cellular mechanism RNA interference (RNAi) for targeted gene silencing.

Photo
12.01.2023 • News

AstraZeneca Buys CinCor Pharma

AstraZeneca has entered into an agreement to buy CinCor Pharma, a US-based clinical-stage biopharma focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.

Photo
05.01.2023 • News

Novartis to Pay $245 Million in ’Pay for Delay’ Settlement

Novartis has agreed to pay a total of $245 million to settle lawsuits filed by direct purchasers, indirect purchasers and retailers accusing it of colluding with Par Pharmaceutical to delay the launch of a generic version of its Exforge (valsartan/amlodipine) hypertension drug.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.